Gyre Therapeutics (NASDAQ:GYRE) reached a critical regulatory milestone as the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) granted Priority Review status to the New Drug Application (NDA) for Hydronidone (F351).
Kalaris (NASDAQ:KLRS) reported its fourth-quarter and full-year 2025 financial results today, delivering a clinical update that positions its lead candidate as a potential disruptor in the $13 billion anti-VEGF market.
Expion360 (NASDAQ:XPON) on Tuesday reported full-year 2025 net sales of $9.7 million for the period ended December 31, 2025, an increase of 72% from the prior year, reflecting continued expansion in lithium battery solutions for recreational vehicles, marine and industrial applications.
Comstock Holding Companies (NASDAQ:CHCI) reported robust financial results for the fourth quarter and full year ended December 31, 2025, extending its streak of year-over-year revenue growth to 28 consecutive quarters.
Lifeway Foods (NASDAQ:LWAY) reported a strong conclusion to its 2025 fiscal year, fueled by consistent volume growth across its core probiotic dairy portfolio.
IceCure Medical (NASDAQ:ICCM) announced record financial results for the fourth quarter and full year ended December 31, 2025, marking a transformative period for the Israeli medtech firm.
Academy Sports + Outdoors (NASDAQ:ASO) reported a solid conclusion to fiscal 2025, with full-year net sales climbing 2% to reach a milestone of $6.05 billion.
Telesat (NASDAQ:TSAT) reported a net loss of $90.1 million for the fourth quarter ended December 31, 2025.
Mastercard (NYSE:MA) today signaled a major shift in the global payments landscape by announcing the acquisition of BVNK, a prominent provider of stablecoin and digital asset infrastructure.
Neuronetics (NASDAQ:STIM), the leader in Transcranial Magnetic Stimulation (TMS) therapy for mental health, reported its fourth-quarter and full-year 2025 financial results, reflecting the transformative impact of its late-2024 acquisition of Greenbrook TMS.
Corporación América Airports (NYSE:CAAP), one of the world's largest private airport operators, delivered a strong finish to fiscal 2025, characterized by robust top-line growth and a dramatic expansion in profitability.
CervoMed (NASDAQ:CRVO) announced on Tuesday that it has achieved critical regulatory and clinical alignment for the Phase 3 development of neflamapimod, its oral small-molecule treatment for dementia with Lewy bodies (DLB).
